The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ...
Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback